Family Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Family Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-3,000	Closed	-$279K	–	62
2017 Q3	$279K	Buy	+3,000	New	+$265K	0.19%	53
2017 Q2	–	Sell	-3,000	Closed	-$263K	–	71
2017 Q1	$263K	Hold	3,000	–	–	0.18%	50
2016 Q4	$249K	Hold	3,000	–	–	0.17%	55
2016 Q3	$278K	Buy	+3,000	New	+$282K	0.16%	61

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Family Management's BMRN Position: Q4 2017 in Review

Family Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2017, closing a stake of 3,000 shares — an estimated $279K sold.

Family Management first reported a position in BMRN in Q3 2016 and held it in 4 quarters. The position peaked at $279K in Q3 2017. 438 funds tracked by Wall St. Rank hold BMRN as of Q4 2017.

Family Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Family Management sold 3,000 BioMarin Pharmaceuticals shares in Q4 2017, an estimated $279K.
Family Management first reported a position in BioMarin Pharmaceuticals in Q3 2016 and held it in 4 quarters.
Family Management's BioMarin Pharmaceuticals position peaked at $279K in Q3 2017.
438 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2017.

Based on Family Management's 13F filing for Q4 2017, filed 15 Feb 2018.